Emcure Pharmaceuticals (EMCURE) Q1 24/25 earnings summary

Executive summary

• Unaudited consolidated and standalone financial results for the quarter ended June 30, 2024, were reviewed and approved by the Board and Audit Committee on August 13, 2024.

• This is the first quarter post-listing of equity shares on NSE and BSE, with prior period comparatives not reviewed by statutory auditors.

Financial highlights

• Consolidated revenue from operations for Q1 FY25 was ₹18,151.38 million, up from ₹15,561.62 million in Q1 FY24.

• Consolidated net profit for the quarter was ₹1,525.90 million, compared to ₹1,409.65 million in Q1 FY24.

• Standalone revenue from operations for Q1 FY25 was ₹9,702.93 million, up from ₹8,369.58 million in Q1 FY24.

• Standalone net profit for the quarter was ₹404.46 million, compared to ₹362.22 million in Q1 FY24.

Outlook and guidance

• Recent business agreements and acquisitions have impacted comparability of current period results with previous periods.